Truvestments Capital’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Truvestments Capital’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-41	Closed	-$14	–	710
2023 Q1	$14	Hold	41	–	–	﹤0.01%	667
2022 Q4	$30	Sell	41 -17	-29%	-$17	﹤0.01%	914
2022 Q3	$0	Hold	58	–	–	﹤0.01%	668
2022 Q2	$0	Buy	+58	New	+$88	﹤0.01%	658
2022 Q1	–	Sell	-58	Closed	–	–	599
2021 Q4	$0	Hold	58	–	–	﹤0.01%	668
2021 Q3	$0	Hold	58	–	–	﹤0.01%	661
2021 Q2	$0	Hold	58	–	–	﹤0.01%	705
2021 Q1	$0	Hold	58	–	–	﹤0.01%	689
2020 Q4	$0	Buy	+58	New	+$245	﹤0.01%	621
2019 Q4	–	Sell	-102	Closed	-$1K	–	648
2019 Q3	$1K	Sell	102 -12	-11%	-$157	﹤0.01%	689
2019 Q2	$2K	Hold	114	–	–	﹤0.01%	694
2019 Q1	$4K	Buy	+114	New	+$3.81K	﹤0.01%	635
2018 Q3	$7K	Buy	+115	New	+$7.79K	﹤0.01%	710

Other funds holding BLCM

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

PGAM

Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Truvestments Capital's BLCM Position: Q2 2023 in Review

Truvestments Capital sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 41 shares — an estimated $14 sold.

Truvestments Capital first reported a position in BLCM in Q3 2018 and held it in 13 quarters. The position peaked at $7K in Q3 2018. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.

Truvestments Capital reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Truvestments Capital sold 41 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $14.
Truvestments Capital first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2018 and held it in 13 quarters.
Truvestments Capital's Bellicum Pharmaceuticals, Inc. position peaked at $7K in Q3 2018.
4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.

Based on Truvestments Capital's 13F filing for Q2 2023, filed 10 Aug 2023.